Regarding: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-α2a compared with sunitinib

British Journal of Cancer

Volumn 102, Issue 7, 2010, Pages 1196-1197

  Porta, C ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; SUNITINIB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; KIDNEY CARCINOMA; LETTER; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG TOXICITY; HEALTH CARE COSTS; HUMANS; INDOLES; INTERFERON ALFA-2A; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PYRROLES;

EID: 77950370961     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605585     Document Type: Letter

References (8)

1. Chen MH (2009) Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep 11: 167-174
2. Di Lorenzo G, Autorino R, Bruni G, Carteǹi G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20: 1535-1542
3. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111
4. Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Delva R, Sevin E, Negrier S, McKendrick J, Santoro A, Pisa P, Escudier B (2008) First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 19: 1470-1476
5. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M (2010) Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-a2a compared with sunitinib. Br J Cancer 102: 80-86
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
7. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81-83
8. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6: 219-228